Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: structural characterization of its zinc(II) and copper(II) complexes.
Clioquinol, a 8-hydroxyquinoline derivative, is producing very encouraging results in the treatment of Alzheimer's disease (AD). Its biological effects are most likely ascribed to complexation of specific metal ions, such as copper(II) and zinc(II), critically associated with protein aggregation and degeneration processes in the brain. We report here, for the first time, a structural characterization of the zinc(II) and copper(II) complexes of clioquinol. A ligand to metal stoichiometry of 2:1 is found in both cases, though in the presence of quite different coordination polyhedra. The present findings are discussed in the frame of modern approaches to AD treatment.
Di Vaira
Massimo
M
Department of Chemistry, University of Florence, via della Lastruccia 3, Sesto Fiorentino, Florence, Italy. massimo.divaira@unifi.it
Bazzicalupi
Carla
C
Orioli
Pierluigi
P
Messori
Luigi
L
Bruni
Bruno
B
Zatta
Paolo
P
D000544:Alzheimer Disease / Q000188:drug therapy*; D001921:Brain / Q000378:metabolism*; D002614:Chelating Agents / Q000737:chemistry* / Q000627:therapeutic use; D007464:Clioquinol / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use; D003300:Copper / Q000737:chemistry*; D018360:Crystallography, X-Ray; D008968:Molecular Conformation; D009942:Organometallic Compounds / Q000737:chemistry*; D015032:Zinc / Q000737:chemistry*
D002614:Chelating Agents; D009942:Organometallic Compounds; D003300:Copper; D007464:Clioquinol; D015032:Zinc